Therapeutic Instillation of Mistletoe (TIM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02106572 |
|
Recruitment Status :
Recruiting
First Posted : April 8, 2014
Last Update Posted : April 26, 2022
|
Sponsor:
Abnoba Gmbh
Information provided by (Responsible Party):
Abnoba Gmbh
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the toxicity of the two treatments. Another secondary objective is the treatment efficacy as measured by calculated prognosis for recurrence and progression after 1 year, the tumor grading in case of a recurrence and by measurement of Quality of Life.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Superficial Bladder Cancer | Drug: abnobaVISCUM 900 Drug: Mitomycin C | Phase 3 |
This is a randomized, open-label, active-controlled, prospective, multinational Phase III confirmative study with 2 treatment groups and an adaptive design (Bauer and Köhne, 1994). The study is designed to compare the efficacy of treatment with abnobaVISCUM® 900 with Mitomycin C (MMC). Patients with completely resected superficial bladder carcinoma (Stage Ta) with an intermediate risk classification according to the European Association of Urology (EAU, update 2013) and with one immediately post operative MMC 40 mg intravesical instillation will be eligible for inclusion in the study.
The study comprises a screening period of not more than 6 weeks, a treatment period of 12 months for abnobaVISCUM® 900 and MMC and a follow-up period of 12 months. Patients will be screened within 6 weeks after the transurethral resection of the bladder (TURB) and the immediately post operative MMC 40 mg intravesical instillation. A re-resection should be performed before inclusion if indicated. Every patient is to provide written informed consent before any study related procedures will be performed.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 546 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | Blind Review in accordance with with ICH-Biostatistics Guideline ICH E9 |
| Primary Purpose: | Treatment |
| Official Title: | Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study |
| Actual Study Start Date : | April 2015 |
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | June 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Bladder cancer
MedlinePlus related topics:
Bladder Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: abnobaVISCUM 900
intravesical instillation of abnobaVISCUM 900
|
Drug: abnobaVISCUM 900
intravesical instillation of abnobaVISCUM 900 13 times during treatment period
Other Names:
|
|
Active Comparator: Mitomycin C
intravesical instillation of Mitomycin C
|
Drug: Mitomycin C
intravesical instillation of Mitomycin C 10 times during treatment period
Other Names:
|
Primary Outcome Measures :
- Time to tumor recurrence [ Time Frame: up to two years ]The primary objective of the study is to assess the efficacy of abnobaVISCUM® 900. Primary efficacy criterion will be the time to tumor recurrence.
Secondary Outcome Measures :
- Toxicity and tolerability of the study medication [ Time Frame: up to two years ]The secondary objective, namely safety including toxicity and tolerability of the study medication, will be assessed by the monitoring of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE), laboratory assessments (hematology, biochemistry and urinalysis) and a global judgment of tolerability.
- Prognosis after 1 year for recurrence and progression [ Time Frame: 1 year ]A secondary efficacy endpoint is prognosis after 1 year for recurrence and progression, estimated by the European Organization for Research and Treatment of Cancer (EORTC) Bladder Cancer Calculator.
- Quality of Life with the EORTC QLQ-C30 and BLS24 Quality of Life Questionnaires [ Time Frame: up to two years ]A secondary efficacy endpoint is measurement of Quality of Life with the EORTC QLQ-C30 and BLS24 questionnaires.
- Tumor grading [ Time Frame: up to two years ]A secondary efficacy endpoint is the tumor grading in case of a recurrence by cytology, ultrasound, and cystoscopy.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed and dated written informed consent for data protection and willingness to participate and comply with the study protocol prior to any study-related procedures
- Completely resected (detrusor muscle in the TUR specimen according to need) superficial bladder carcinoma (Stage Ta) with classification as intermediate-risk according to the EAU (update 2013) and one immediately post operative intravesical MMC instillation of 40 mg, completed re-resection if indicated
- Karnofsky Performance Status of 50% to 100% (corresponding to Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2)
- Life expectancy of ≥ 2 years at the time point of study inclusion
- Normal renal and liver function, normal cardiac and hematology profiles (patients with laboratory values slightly outside the reference range may be included, unless the investigator considers the abnormality as clinically significant)
- Female patients of childbearing potential must have a negative pregnancy test (β-human chorionic gonadotropin test) at Screening. Pregnancy during the treatment period including 12 weeks after the last instillation has to be excluded
Exclusion Criteria:
- Locally infiltrative or metastatic bladder tumor (Stage T2 or greater), low-risk Ta tumor (primary, solitary, LG/G1, <3 cm, no CIS) or high-risk tumors according to EAU classification, update 2013 (T1; HG/G3; CIS; multiple and recurrent and large [>3 cm] Ta G1/G2 tumors [all conditions must be present at this point], presence of upper urinary tract tumors or lesions which were not completely removed by TURB
- Urinary tract infection, benign prostatic obstruction grade II or III, neurogenic bladder, stress incontinence, bladder or urethral diverticula, fistulas or urethral stenosis
- Patients with acute systemic illness, such as inflammatory infections with fever > 38°C
- Patients with previous recurrence of a superficial bladder cancer or radiotherapy of the bladder or other intravesical treatment within the last 6 months, or patients with previous mistletoe therapy
- Patients with other previous or co-existing malignancies or CIS
- Patients having any previous or concurrent therapy with a systemic chemo- / immunotherapeutical treatment regimen, in particular vinca alkaloids, bleomycine and doxorubicine, or patients who are treated with pyroxidine hydrochloride (vitamin B6)
- Untreated coagulation disorders or inadequate anticoagulation therapy
- Leukocyte count < 4,000/mm3 or platelet count < 100,000/mm3
- Serum creatinine > 1.7 mg/dL
- Patients with known hypersensitivity to the excipients of the study medication (monosodium phosphate, disodium phosphate, ascorbic acid)
- Patients with a known hypersensitivity to mistletoe products and MMC
- Patients who were administered within a 4-week period before Visit 1 any other experimental drug under investigation
- Male patients planning to father a child or sperm donation from the first administration of study medication until 3 months after the last administration of the study medication
- Male patients unwilling to use barrier contraception ie, condoms and spermicide, from the day of first administration of the study medication until 12 weeks after administration of the study medication. In case the sexual relation is restricted to women fulfilling one of the criteria listed under inclusion criteria for female patients the barrier contraception is not necessary.
- Patients with a history of alcohol and / or drug abuse
- Patients who are unable to be regularly observed, not permitting adequate follow-up and compliance to the protocol
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02106572
Contacts
| Contact: Juergen Eisenbraun, Dr. | +49 7233 7043 200 | eisenbraun@abnoba.de |
Locations
Show 19 study locations
Sponsors and Collaborators
Abnoba Gmbh
Investigators
| Principal Investigator: | Stephan Tschirdewahn, Dr. | Senior Physician of the Urological Clinic of the University Hospital Essen |
| Responsible Party: | Abnoba Gmbh |
| ClinicalTrials.gov Identifier: | NCT02106572 |
| Other Study ID Numbers: |
AB03 2013-003446-16 ( EudraCT Number ) |
| First Posted: | April 8, 2014 Key Record Dates |
| Last Update Posted: | April 26, 2022 |
| Last Verified: | April 2022 |
Keywords provided by Abnoba Gmbh:
|
superficial bladder cancer viscum album extract mistletoe extract abnobaVISCUM recurrence rate |
Additional relevant MeSH terms:
|
Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Urinary Bladder Diseases Urologic Diseases Viscum album peptide Mitomycins Mitomycin |
Antibiotics, Antineoplastic Antineoplastic Agents Alkylating Agents Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |